• Explore /
  • Poster
  • / Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.

Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

Michael Morris

Michael J. Morris

Memorial Sloan Kettering Cancer Center, New York, NY

Michael J. Morris , Mark David Linch , Simon J. Crabb , Tomasz M. Beer , Elisabeth I. Heath , Michael S. Gordon , Johann S. De Bono , Hristina I Pashova , Iulia Cristina Tudor , Andrew E Greenstein , Grace Mann , Glenn Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03437941

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 145)

DOI

10.1200/JCO.2023.41.6_suppl.145

Abstract #

145

Poster Bd #

E6

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Michael C. Burns

First Author: D. B. Agus

First Author: Christos Kyriakopoulos

First Author: Dana E. Rathkopf